ANDA 90022, held by Sun Pharm. Alendronate Sodium.
As of Nov 16, 2026, ANDA 90022 (Alendronate Sodium), held by Sun Pharm, was first approved by FDA on Sep 10, 2008, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Apr 8, 2016 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 7, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 28, 2012 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 1, 2011 | Supplement 6REMS | Approved | None posted |
| Apr 5, 2011 | Supplement 5Labeling | Approved | None posted |
| Nov 29, 2010 | Supplement 4Labeling | Approved | None posted |
| Nov 17, 2009 | Supplement 2Labeling | Approved | None posted |
| Sep 10, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters